the manufacturing platform of flash therapeutics

A CDMO expert in lentiviral manufacturing

COVID-19 RELATED MEASURES

Flash Therapeutics resumed its production and analytical activities on Monday March 23rd in order to ensure the follow-up of our clinical research work, as well as that of our partners and customers. As soon as the technical activities are completed, the concerned teams will return home and ensure traceability and follow-up remotely. All managers are committed to organizing the daily routine and logistics around on-site activities to ensure the safety of our employees present. Since the beginning of this health crisis, and in compliance with government regulations, all Flash Therapeutics’ employees who are able to continue their work remotely have been able to do so from home. All Flash Therapeutics’ employees are now connected from home. Should government measures change then we will keep you informed of our activity

our technology

RNA and DNA carriers from R&D grade to clinical applications

Lentiviral vectors for a stable expression
LentiFlash particles for non-integrative RNA delivery

lentiviral manufacturing platform

A continuum from research to clinical studies

applications of lentiviral technologies

The choice of lentiviral technology depends on your application

Gene editing Gene addition Immunotherapy Stable cell lines

news & events

Stay updated with our latest events and breaking news

Discover our Latest blog post

CRISPR/Cas 9 system: a story of off target and DNA repair control

30-03-2020Essentials
Blog
Newsletter

GMP lentiviral particle manufacturing facilities to produce gene & cell therapy drugs

While supplying high quality vectors for research and preclinical purpose, the Vectalys’ platform is now accelerating its development by providing cGMP compliant large-scale lentiviral vectors for clinical applications on two sites in Paris and Toulouse (France) for different phases in GMP process.
 Subscribe to our newsletter
News & events
All news & events